Triclosan promotes liver tumors, health costs of EDC exposure, and more // Dec 2014 science update #2

December 15, 2014 at 2:46 pm | Posted in Uncategorized | Leave a comment

December 2014 Science Digest #2:
Non-Human and Policy Research

Obesity, flame retardants | Ligand Binding and Activation of PPARγ by Firemaster® 550: Effects on Adipogenesis and Osteogenesis in Vitro. Study suggesting that FM550 components bind and activate PPARγ, initiating adipocyte differentiation and antagonizing osteogenesis. Triphenyl phosphate (TPP), a component of FM550, likely is a major contributor to these biological actions. Given that TPP is ubiquitous in house dust, further studies are warranted to investigate the health effects of FM550.

Liver cancer, triclosan | The commonly used antimicrobial additive triclosan is a liver tumor promoter. A long-term feeding study finding that TCS enhances hepatocyte proliferation, fibrogenesis, and oxidative stress, which may be the driving force for developing advanced liver disease in mice. TCS strongly enhanced hepatocarcinogenesis after diethylnitrosamine initiation, accelerating hepatocellular carcinoma (HCC) development. Although animal studies require higher chemical concentrations than predicted for human exposure, this study demonstrates that TCS acts as a HCC tumor promoter.

EDCs, health costs | The Cost of Inaction : A Socioeconomic analysis of costs linked to effects of endocrine disrupting substances on male reproductive health. A Nordic Council of Ministers report on costs of EDC exposure. “Assuming that EDs constitute 2, 20 or 40% the total costs for the selected health effects are 3.6, 36.1 or 72.3 million Euros/year of exposure in the Nordic countries, this corresponds to 59, 592 and 1,184 million Euros/year at EU-level. As these costs only represent a fraction of the endocrine related diseases there are good reasons to continue the work to minimize exposure to EDs.”

BPA, exposure estimates | Evidence that bisphenol A (BPA) can be accurately measured without contamination in human serum and urine and that BPA causes numerous hazards from multiple routes of exposure. NIH and industry-sponsored round robin studies have demonstrated that serum BPA can be accurately assayed without contamination; however, the FDA lab has acknowledged uncontrolled assay contamination and suggested all BPA research suffers from this problem. In reviewing the published BPA biomonitoring data, the authors find that assay contamination is, in fact, well controlled in most labs, and cannot be used as the basis for discounting evidence that significant and virtually continuous exposure to BPA must be occurring from multiple sources.

Leave a Comment »

RSS feed for comments on this post. TrackBack URI

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

Blog at
Entries and comments feeds.

%d bloggers like this: